Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
AssigneeAstra Aktiebolag
InventorsArne T. Eek, Sven E. Sjostrand
Life of this patent
Estimating the term…
Abstract
A synergistic pharmaceutical combination or composition is disclosed for the treatment of gastritis and peptic ulcer containing a therapeutic amount of a histamine H.sub.2 receptor blocking agent, which increases intragastric pH, and an acid degradable antibacterial compound. In particular, the combination is directed to the treatment of infections by Helicobacter pylori by raising the bioavailability of acid degradable antibacterial compounds.
Claims13
A pharmaceutical composition for the treatment of gastritis and peptic ulcer, comprising a therapeutically effective amount of a histamine-H.sub.2 receptor blocking compound which increases intragastric pH and a therapeutically effective amount of an acid degradable antibacterial compound.
An oral pharmaceutical composition for the treatment of gastritis and peptic ulcer caused by Helicobacter pylori infections comprising as active ingredients,
- (a) a therapeutically affective amount of a histamine-H.sub.2 blocker which is a compound with inhibiting effect on the gastric acid secretion which effect increases the intragastric pH;
- and
- (b) a therapeutically affective amount of an acid degradable antibacterial compound.
A synergistic pharmaceutical combination comprising from about 1 to 200 mg histamine-H.sub.2 blocker and from about 250 mg to 10 g of an acid degradable antibacterial compound for the treatment of gastritis and peptic ulcer.
A synergistic pharmaceutical combination of a therapeutically acceptable amount of a histamine H.sub.2 blocker and a therapeutically acceptable amount of an acid degradable antibacterial compound selected from the group consisting of an erythromycin, a clarithromycin and a penicillin for the oral treatment of gastritis and peptic ulcer.
A method for treatment of gastritis and peptic ulcer caused by Helicobacter pylori comprising orally first administering to a patient suffering therefrom a pharmaceutical composition comprising a therapeutically effective amount of a histamine-H.sub.2 blocker which is an inhibitor of the gastric acid secretion, and pharmaceutically acceptable carrier;
- and thereafter and concomitantly administering a therapeutically effective amount of at least one acid degradable antibacterial compound.
Dependencies are inferred from the claim text.